Renal targeted delivery of triptolide by conjugation to the fragment peptide of human serum albumin

Yuan, Zhixiang; Wu, Xiaojuan; Mo, Jingxin; Wang, Yanli; Xu, Chunping; Lim, Lee Yong

doi:10.1016/j.ejpb.2015.06.012

Cited by 39 publications

(22 citation statements)

References 30 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the data from the included studies, 0.5 to 1.5 mg·kg −1 ·day −1 of TwHF is recommended in future clinic application with less toxicity. Some researches also had attempted the following approaches to decrease its toxicity: (a) modify structure of its bioactive substances; (b) combine compounds reasonably; (c) purify its extracts; (d) optimize its extraction methods; and (e) change its formulations and administration methods (Hewitson, Ignatova, Ye, Chen, & Sutherland, 2009;Li et al, 2017;Nan, Zheng, & Xu, 2015;Shao et al, 2006;Tang & Zuo, 2012;Yuan et al, 2015;Zhang et al, 2014a;Zhang et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of Tripterygium wilfordii Hook F for CKD in Mainland China: A systematic review and meta‐analysis

Wang

Zhao

Cui³

et al. 2017

Phytotherapy Research

View full text Add to dashboard Cite

Tripterygium wilfordii Hook F (TwHF) is a promising Chinese traditional medicine used to significantly reduce proteinuria and improve renal function. However, its efficacy and safety in treatment of chronic kidney disease need to be further explored in order to promote its application in clinics. This review compared the efficacy and safety of TwHF with the placebo, conventional Western medicine and other immunosuppressive medicine in a range of kidney disorders. One hundred three randomized controlled trials were included. TwHF therapy decreased 24-hr proteinuria by 0.59 g/day (95% confidence interval [CI; -0.68, -0.50]), serum creatinine level by 1.93 μmol/L (95% CI [-3.69, -0.17]), and blood urea nitrogen level by 0.24 mmol/L (95% CI [-0.41, -0.07]); increased the total effective rate by 27% (95% CI [1.24, 1.30]); and decreased the incidence of adverse reactions by 19% (95% CI [0.68, 0.96]) overall. Meta regression results showed that the duration of therapy and mean age of participants were the major sources of high heterogeneity. Sensitivity analysis demonstrated that our statistic results were relatively stable and credible. The present findings suggested that TwHF possibly has nephroprotective effects by decreasing proteinuria, serum creatinine level, and blood urea nitrogen level and no more adverse reactions compared with control group in most kidney disorders. However, these findings still need to be further confirmed by high-quality trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of Tripterygium wilfordii Hook F for CKD in Mainland China: A systematic review and meta‐analysis

Wang

Zhao

Cui³

et al. 2017

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…The MN model was established in all except rats in the normal group according to our previous method. 11 In brief, cationic bovine serum albumin (C-BSA, 1 mg emulsified in 0.5 mL of Freund's complete adjuvant) was subcutaneously injected into the rats to initiate the immunization. One week later, rats were immunized intravenously with 2.5 mg C-BSA every other day for another 2 weeks to finally establish the MN rat model.…”

Section: Treatment Of Nephropathic Ratsmentioning

confidence: 99%

“…[24][25][26] To improve its therapeutic potential, much research has been focused on employing appropriate pharmaceutical strategies to attenuate the toxicity and increase the water solubility of TP. 11,[27][28][29] In this study, the entrapment of TP into 11%-TRX-LP to fabricate TRX-TP-LP did not change the diameter and zeta potential of the liposomes. PEGylation of TRX-TP-LP led to an increase in diameter but had no effect on the zeta potential.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Renal-targeted delivery of triptolide by entrapment in pegylated TRX-20-modified liposomes

Yuan

Jia

Lim

et al. 2017

IJN

Self Cite

View full text Add to dashboard Cite

Previously, 3,5-dipentadecyloxybenzamidine hydrochloride (TRX-20)-modified liposomes were reported to specifically target mesangial cells (MCs) in glomeruli. To further gain a better understanding of the characteristics and potential application for glomerular diseases of TRX-20-modified liposomes, we synthesized TRX-20 and prepared TRX-20-modified liposomes (TRX-LPs) with different molar ratios – 6% (6%-TRX-LP), 11% (11%-TRX-LP), and 14% (14%-TRX-LP) – of TRX-20 to total lipid in the present study. All TRX-LPs exhibited concentration-dependent toxicity against the MCs at a lipid concentration ranging from 0.01 to 1.0 mg/mL with IC 50 values of 3.45, 1.13, and 0.55 mg/mL, respectively. Comparison of the cell viability of TRX-LPs indicated that high levels of TRX-20 caused severe cell mortality, with 11%-TRX-LP showing the higher cytoplasmic accumulation in the MCs. Triptolide (TP) as a model drug was first loaded into 11%-TRX-LP and the liposomes were further modified with PEG 5000 (PEG-TRX-TP-LP) in an attempt to prolong their circulation in blood and enhance TP-mediated immune suppression. Due to specific binding to MCs, PEG-TRX-TP-LP undoubtedly showed better anti-inflammatory action in vitro, evidenced by the inhibition of release of nitric oxide (NO) and tumor necrosis factor-α from lipopolysaccharide-stimulated MCs, compared with free TP at the same dose. In vivo, the PEG-TRX-TP-LP effectively attenuated the symptoms of membranous nephropathic (MN) rats and improved biochemical markers including proteinuria, serum cholesterol, and albumin. Therefore, it can be concluded that the TRX-modified liposome is an effective platform to target the delivery of TP to glomeruli for the treatment of MN.

show abstract

“…27,103 In vivo data obtained in a comparative study of the TP-PF-A 299-585 conjugate and the free TP in the MN rat model showed that TP conjugated to PF-A 299-585 was more effective at relieving the nephropathic symptoms and significantly less toxic than the free TP. 27 Teekamp et al 104 attached HSA to multiple platelet-derived growth factor receptor β (PDGFβR)-recognizing moieties (pPB) and then encapsulated this in polymer microspheres to form an injectable sustained release formulation of pPB-HSA. After subcutaneous injection of the microspheres into mice, the pPB-HSA was found to accumulate at a three-fold higher level in the fibrotic kidney compared to the healthy kidney on day 7.…”

Section: Protein-based and Peptide-based Carriersmentioning

confidence: 99%

Targeting strategies for drug delivery to the kidney: From renal glomeruli to tubules

Liu

Lin

et al. 2018

Medicinal Research Reviews

Self Cite

View full text Add to dashboard Cite

Kidney diseases have become a global public health problem. The application of kidney-targeted drug-delivery systems in the management of kidney diseases has profound transformative potential. Kidney-targeted drug delivery can reduce the undesired side effects of often potent drugs and enhance drug efficacy in alleviating the kidney disease. Here, we review the literature on the potential strategies for targeting drugs to the kidneys. Specifically, we provide a broad overview of the targeting vectors and targeting pathways for renal tubules and glomeruli, as well as how the unique structural features of the glomerulus and the receptor-mediated internalization pathways of the tubules allows for drug targeting. Finally, we summarized the literature examples of drug delivery to the kidneys and elaborated strategies suitable for renal targeting to provide new therapeutic approaches for kidney diseases.

show abstract

Renal targeted delivery of triptolide by conjugation to the fragment peptide of human serum albumin

Cited by 39 publications

References 30 publications

Efficacy and safety of Tripterygium wilfordii Hook F for CKD in Mainland China: A systematic review and meta‐analysis

Efficacy and safety of Tripterygium wilfordii Hook F for CKD in Mainland China: A systematic review and meta‐analysis

Renal-targeted delivery of triptolide by entrapment in pegylated TRX-20-modified liposomes

Targeting strategies for drug delivery to the kidney: From renal glomeruli to tubules

Contact Info

Product

Resources

About